Zhejiang Sunflower Great Health Technology Co., Ltd. announced that its subsidiary Zhejiang Beide Pharmaceutical Co., Ltd. has received a Drug Registration Certificate for Glucosamine Sulfate Capsules issued by the National Medical Products Administration. The specifications are 0.25 grams or 0.314 grams, the registration classification is Category 4 chemical drug, it is managed as a Class A over-the-counter drug, and it is deemed to have passed the consistency evaluation. The drug is indicated for primary and secondary osteoarthritis. The original innovative drug was approved for marketing in China in 1996 and has been included in Category B of the national medical insurance drug list. The company received the notice of acceptance on March 10, 2025, and was approved recently. The company stated that this approval will improve its product structure and enhance market competitiveness, while also noting that production and sales are subject to uncertainties arising from policies, regulations, and the market environment.
Zhejiang Sunflower Light EnergySubsidiary Zhejiang Beide Pharmaceutical received a Drug Registration Certificate from the National Medical Products Administration for Glucosamine Sulfate Capsules, improving its product structure and market competitiveness.
